Open AccessINTRAUTERINEINJECTION OF PROSTAGLANDIN F 2α FOR TERMINATION OF EARLY PREGNANCY IN OUT‐PATIENT
Author(s) -
Ylikorkala O.,
Jouppila P.,
Ylöstalo P.,
Jαrvinen P. A.
Publication year - 1974
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016347409156411
Subject(s) - medicine , curettage , premedication , pregnancy , abortion , products of conception , prostaglandin , menstruation , obstetrics , amenorrhea , anesthesia , gynecology , surgery , genetics , biology
. Prostaglandin F 2α administered as single intrauterine injection was used for termination of very early pregnancy in 34 outpatients. Twelve patients were induced with 1.0 mg, 18 patients with 2.0 mg and 4 patients with 4.0 mg of PGF 2α . After 2 weeks, abortion was complete in 58 % induced with 1.0 mg, in 78 % induced with 2.0 mg, and in all 4 patients induced with 4.0 mg. After 3 weeks, abortion was complete in 83 % induced with 1.0 mg and in 100% induced with 2.0 mg. There was one failure, which occurred in the group treated by using 1.0 mg PGF 2α . Immediate sideeffects were kept at an acceptable level with a very mild premedication. No serious complications occurred but curettage was performed on 2 patients because of bleeding. Spontaneous menstruation started in the 1.0 mg group within an average of 33 days (range 23‐60), in the 2.0 mg group within an average of 36 days (range 25‐61). The use of 2.0 mg PGF 2α for the routine termination of very early pregnancy is recommended.